of data
support
quality of product
Stock Locations
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Stock subject to availability.
Documentation
Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.
Ombitasvir Impurity 2
● In Stock
| Catalogue No.: | VE0021843 |
|---|---|
| CAS No.: | N/A |
| Mol. Formula: | C50H67N7O8 |
| Mol. Weight: | 894.11 g/mol |
Additional information on Ombitasvir Impurity 2
Parent drug
OmbitasvirIUPAC Name
Dimethyl ((2R, 2’R)-((2S, 2’S)-2, 2′-(((((2R, 5R)-1-(4-(tert-butyl)phenyl)pyrrolidine-2, 5-diyl)bis(4, 1-phenylene))bis(azanediyl))bis(carbonyl))bis(pyrrolidine-2, 1-diyl))bis(3-methyl-1-oxobutane-2, 1-diyl))dicarbamatePharmacopoeial Synonyms
N/AOther Synonyms
Dicarbamate, dimethyl ((2R, 2’R)-((2S, 2’S)-2, 2′-(((((2R, 5R)-1-(4-(tert-butyl)phenyl)pyrrolidine-2, 5-diyl)bis(4, 1-phenylene))bis(azanediyl))bis(carbonyl))bis(pyrrolidine-2, 1-diyl))bis(3-methyl-1-oxobutane-2, 1-diyl))Smiles
CC(C1=CC=C(N2[C@@H](C3=CC=C(NC([C@H]4N([C@@](C(C)C)(NC(OC)=O)C=O)CCC4)=O)C=C3)CC[C@@H]2C5=CC=C(NC([C@H]6N([C@@](C(C)C)(NC(OC)=O)C=O)CCC6)=O)C=C5)C=C1)(C)CInChI
InChI=1S/C50H67N7O8/c1-32(2)49(30-58, 53-46(62)64-8)55-28-10-12-42(55)44(60)51-37-20-14-34(15-21-37)40-26-27-41(57(40)39-24-18-36(19-25-39)48(5, 6)7)35-16-22-38(23-17-35)52-45(61)43-13-11-29-56(43)50(31-59, 33(3)4)54-47(63)65-9/h14-25, 30-33, 40-43H, 10-13, 26-29H2, 1-9H3, (H, 51, 60)(H, 52, 61)(H, 53, 62)(H, 54, 63)/t40-, 41-, 42+, 43+, 49+, 50+/m1/s1Description
Ombitasvir Impurity 2 | also known as Dicarbamate | dimethyl ((2R | 2’R)-((2S | 2’S)-2 | 2′-(((((2R | 5R)-1-(4-(tert-butyl)phenyl)pyrrolidine-2 | 5-diyl)bis(4 | 1-phenylene))bis(azanediyl))bis(carbonyl))bis(pyrrolidine-2 | 1-diyl))bis(3-methyl-1-oxobutane-2 | 1-diyl)) is a highly characterized reference material. It fully complies with stringent regulatory standards | including those set by USP | EMA | JP | and BP. This product is essential for use in Abbreviated New Drug Applications (ANDA) | New Drug Applications (NDA) | and the commercial production of Ombitasvir. Moreover | it comes with a detailed Structure Elucidation Report (SER) | ensuring its accuracy and reliability for a wide range of analytical applications.
Request a Quote
"*" indicates required fields
